Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Bayer Licenses Trius Antibiotic
by Lisa M. Jarvis
August 1, 2011
| A version of this story appeared in
Volume 89, Issue 31
Bayer Pharma will pay Trius Therapeutics $25 million up front for regional rights to torezolid, an antibiotic against gram-positive bacteria that is in Phase III trials to treat acute bacterial skin and skin structure infections (ABSSSI). The San Diego-based firm will allow Bayer to develop the antibiotic in Africa, Latin America, the Middle East, and Asia excluding North and South Korea. Bayer will pay 25% of the costs necessary to gain approval for torezolid as a treatment for ABSSSI and pneumonia, and potentially pay up to $69 million more in milestones.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter